Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 |
| May 27, 2026 |
| clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06551142 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)(PanTumor-101) | recruiting | Phase 1 | 845 | GlaxoSmithKlineINDUSTRY | 13 | May 22, 2026 | clinicaltrials |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | recruiting | Phase 1 / Phase 2 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06898957 | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)((DeLLphi-310)) | active not recruiting | Phase 1 | 29 | AmgenINDUSTRY | 10 | May 20, 2026 | clinicaltrials |
| NCT07481357 | A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 | 51 | Dong-A ST Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT00629759 | A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma | completed | Phase 1 | 14 | Jennerex BiotherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT04742101 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 57 | Institut de Recherches Internationales ServierOTHER | 6 | May 18, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | terminated | Phase 1 / Phase 2 | 124 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 10 | May 13, 2026 | clinicaltrials |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)(Morpheus Lung) | terminated | Phase 1 / Phase 2 | 314 | Hoffmann-La RocheINDUSTRY | 7 | May 12, 2026 | clinicaltrials |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC(MAGELLAN) | active not recruiting | Phase 1 | 175 | AstraZenecaINDUSTRY | 9 | May 12, 2026 | clinicaltrials |
| NCT04817007 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | active not recruiting | Phase 1 / Phase 2 | 216 | Bristol-Myers SquibbINDUSTRY | 11 | May 8, 2026 | clinicaltrials |
| NCT05954312 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 290 | Vividion Therapeutics, Inc.INDUSTRY | 3 | May 8, 2026 | clinicaltrials |
| NCT07371104 | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | recruiting | Phase 1 | 40 | Daewoong Pharmaceutical Co. LTD.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06555744 | A Study of ZW191 in Participants With Solid Tumors | active not recruiting | Phase 1 | 145 | Zymeworks BC Inc.INDUSTRY | 6 | May 7, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT06268613 | A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | active not recruiting | Phase 1 | 163 | Samsung Bioepis Co., Ltd.INDUSTRY | 4 | May 5, 2026 | clinicaltrials |
| NCT05618028 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | active not recruiting | Phase 1 | 78 | AbbVieINDUSTRY | 10 | May 4, 2026 | clinicaltrials |
| NCT03802071 | A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 44 | Yonsei UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06552559 | Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma(SIENA) | recruiting | Phase 1 / Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05975073 | A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors | completed | Phase 1 / Phase 2 | 53 | AmgenINDUSTRY | 7 | Apr 22, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT03317743 | Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04174716 | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)(VASTUS) | completed | Phase 1 / Phase 2 | 108 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 87 | Idience Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT04557150 | A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) | completed | Phase 1 | 225 | Hoffmann-La RocheINDUSTRY | 9 | Apr 13, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 188 | Ascendis Pharma Oncology Division A/SINDUSTRY | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | active not recruiting | Phase 1 | 169 | IDEAYA BiosciencesINDUSTRY | 7 | Apr 9, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT04938583 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | CanariaBio Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03744468 | Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 147 | BeiGeneINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients | terminated | Phase 1 / Phase 2 | 19 | Therapex Co., LtdINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT04903197 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT03449381 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | completed | Phase 1 | 266 | Boehringer IngelheimINDUSTRY | 11 | Mar 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials